The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Roche’s Susvimo (ranibizumab PDS), which launched in November 2021 in the United States, will also attract a small patient share because of its less frequent dosing regimen of once every six months. Additionally, we expect Roche / Chugai’s Vabysmo (faricimab), which launched in the United States in February 2022 and was approved in Japan in March 2022, will see strong uptake driven by its new mechanism of action (MOA) and advantageous dosing regimen. Vabysmo was approved by the FDA in January 2022, making it the first bispecific antibody to launch in the ophthalmology space. Nevertheless, the mainstay anti-VEGF therapies will face competition from the growing number of therapies for wet AMD in the late-phase pipeline, including biosimilar agents. In contrast to wet AMD, the management of dry AMD is limited because no prescription therapies are approved for this large subpopulation. Despite recent setbacks in the clinical development of some late-phase dry AMD therapies, other agents are progressing, such as Apellis’s pegcetacoplan and Iveric Bio’s Zimura, increasing the likelihood that an effective therapy may soon emerge.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 31 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total prevalence of late AMD by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2030, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III / PR: 8 drugs; Phase II: 15 drugs; coverage of select Phase I products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.